CAJ | 학술논문

目的根据单中心资料对男性乳腺癌患者的临床病理学特点及疾病预后进行分析。方法对2000年1月1日至2011年4月30日在中山大学肿瘤防治中心接受治疗的25名男性乳腺癌患者病例资料进行分析，中位随访时间为51个月( 1～90个月)。纳入分析的参数包括肿瘤家族史、年龄、吸烟、酗酒、肿瘤部位、肿瘤象限、病理类型、雌激素受体、孕激素受体、表皮生长因子受体-2、Ki-67、血管内皮生长因子、P53蛋白、新辅助化疗、手术方式、辅助化疗、辅助放疗、辅助内分泌治疗、肿瘤大小、淋巴结转移、远处转移及肿瘤TNM分期。通过单因素分析评价这些参数对患者生存的影响。结果患者的5年生存率为66.5％，新辅助化疗、肿瘤大小、淋巴结转移、远处转移及TNM分期是影响患者生存的独立预后因素，接受了辅助内分泌治疗的患者有更好的预后(P=0.086)。接受新辅助化疗的患者预后差于不接受新辅助化疗的患者(P=0.000)，早期患者预后好于晚期患者(P=0.000)。结论男性乳腺癌患者5年生存率为66.5％，新辅助化疗、肿瘤大小、淋巴结转移、远处转移及TNM分期是影响患者生存的独立预后因素。
목적 근거단중심자료대남성유선암환자적림상병이학특점급질병예후진행분석。방법대2000년1월1일지2011년4월30일재중산대학종류방치중심접수치료적25명남성유선암환자병례자료진행분석，중위수방시간위51개월( 1～90개월)。납입분석적삼수포괄종류가족사、년령、흡연、후주、종류부위、종류상한、병리류형、자격소수체、잉격소수체、표피생장인자수체-2、Ki-67、혈관내피생장인자、P53단백、신보조화료、수술방식、보조화료、보조방료、보조내분비치료、종류대소、림파결전이、원처전이급종류TNM분기。통과단인소분석평개저사삼수대환자생존적영향。결과환자적5년생존솔위66.5％，신보조화료、종류대소、림파결전이、원처전이급TNM분기시영향환자생존적독립예후인소，접수료보조내분비치료적환자유경호적예후(P=0.086)。접수신보조화료적환자예후차우불접수신보조화료적환자(P=0.000)，조기환자예후호우만기환자(P=0.000)。결론남성유선암환자5년생존솔위66.5％，신보조화료、종류대소、림파결전이、원처전이급TNM분기시영향환자생존적독립예후인소。
Abstract: Objective To investigate general and clinicopathological characteristics of male breast cancer and analyzed the factors affecting the outcomes of the patients based on the data from a single institution. Methods Twenty-five male breast cancer patients treated at Sun Yet-sen University Cancer Center between January 1, 2000 and April 30, 2011 were included into the study. The patients were followed up for 1 to 90 months with a median follow-up of 51 months. The general and clinicopathological characteristics including family history, age, smoking, alcohol drinking, site of tumor, location of tumor, histological type, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), Ki-67, vascular endothelial growth factor (VEGF), P53 expression, neoadjuvant chemotherapy, surgery, adjuvant chemotherapy, adjuvant radiotherapy, adjuvant endocrine therapy, tumor size, lymph node status, distant metastasis and TNM stage were investigated by univariate analysis to evaluate the impact of these factors on patient survival. Results The 5-year survival rate was 66.5％ in these patients. Neoadjuvant chemotherapy, tumor size, lymph node status, distant metastasis and TNM stage were significant predictors for the overall survival. Patients receiving adjuvant endocrine therapy tended to have a better overall survival, though this was not supported statistically (P=0.086). However, patients with neoadjuvant chemotherapy had a poorer overall survival than those without it (P=0.000). Patients in stages Ⅰ and Ⅱ had better overall survival than those in stages Ⅲ and Ⅳ (P=0.000). Conclusion The 5-year survival rate was 66.5％in these male breast cancer patients. Neoadjuvant chemotherapy, tumor size, lymph node status, distant metastasis and TNM stage are significant predictors of the overall patient survival.